Switching to guselkumab for inflammatory bowel disease after ustekinumab
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with Crohn's disease, ulcerative colitis, or IBD unclassified for at least 6 months.
- You have been on ustekinumab for at least 14 weeks and are either still on it or stopped it within the last 12 weeks.
- You have not started any other advanced IBD medicine since stopping ustekinumab.
- You have active disease seen on a colonoscopy within the last 3 months, like sores or inflammation.
- You have never taken risankizumab or mirikizumab before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
This study tests whether guselkumab (a targeted drug) can effectively treat Crohn's disease in the ileum (last part of the small intestine). You will have ultrasound scans and blood tests to measure your response, which may help find the right dose and monitor for bowel healing.
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
Hear when a new IBD-unclassified (IBD-U) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.